Foundation for the National Institutes of Health (FNIH): Accelerating Medicines Partnership Type 2 Diabetes (AMP T2D)

AMP T2D aims to provide public access to high-quality human genetic and phenotypic data to allow evaluation of novel therapeutic targets for T2D and its complications. The strategy will be to integrate human genetics data through analysis of natural variations in human protein expression in order to identify and validate targets in vivo. Mutations of known molecular effect (e.g., loss of function) resulting in a desirable clinical outcome (e.g., protection from disease) without adverse consequences will be of special interest. Annotation of noncoding genetic variants associated with T2D, T2D-related quantitative traits, and T2D complications to enable identification of related gene targets will also be of importance.
http://fnih.org/work/key-initiatives/amp-type2-diabetes 
Enhancement of AMP T2D Knowledge Portal
The successful organization(s) will provide a detailed plan to expand and enhance the currently existing NIH-funded Knowledge Portal prototype developed by the Broad Institute. The proposed work will result in an open-access knowledge portal for use by the broad scientific community. The work on the portal would consist of the following development modules: (1) Database integration (2) Genomic and Phenotypic Data Quality Control (3) Analytic tools (4) User Interface for the Portal (5) Integration of all the above components. Funding: Up to a total of $3M over 2 years.
 http://bit.ly/Up6DwR  
Genotypic and Phenotypic Data for AMP T2D Knowledge Portal
FNIH has specific interest in the human genotypic data from well phenotyped cohorts associated with the following: Genome-wide association studies (GWAS), exomes, genomes, and/or exome chip with corresponding with relevant individual level phenotype data, which may include (but is not limited to) the following:
x T2D status, sex, study age, age at diagnosis (if type 2 diabetes)
x Fasting and 2-hour glucose, insulin, C-peptide
x HbA1c, GAD Ab
x Adiponectin, leptin, creatinine
x Total cholesterol, LDL-C, HDL-C, triglycerides
x BMI, hip, waist, height, weight
x SBP, DBP
x DM, HT, lipid medsJ female hormone use
x Datasets that may enable identification of mutations of known molecular effect (e.g., loss of function) that result in a desirable clinical outcome (e.g., protection from disease) without adverse consequences.
Data provided should be able to answer the following queries: phenotype-based, gene- or pathway-based, variant-based and Subset. Funding: $100,000-$300,000 for 1-2 years.
http://bit.ly/1jT4UMr